AMGN registry changes
Status changes, moved primary completion and completion dates, and results first posted on ClinicalTrials.gov, for trials linked to listed companies. Newest detection first.
Newest change detected Nov 19, 2026, 8:47 AM ET
| Detected | Trial | Change | Now | Before | Record updated |
|---|---|---|---|---|---|
| Nov 19, 2026, 8:47 AM ET | Completion date | Jul 31, 2026 (actual) | Locked | Locked | |
| Nov 16, 2026, 8:47 AM ET | Completion date | Oct 26, 2026 (actual) | Locked | Locked | |
| Nov 16, 2026, 8:47 AM ET | Primary completion date | Jul 9, 2026 (actual) | Locked | Locked | |
| Nov 16, 2026, 8:47 AM ET | Status | Completed | Locked | Locked | |
| Nov 13, 2026, 9:47 AM ET | Status | Recruiting | Locked | Locked | |
| Nov 12, 2026, 8:11 AM ET | Completion date | Jul 29, 2032 (sponsor estimate) | Locked | Locked | |
| Nov 12, 2026, 8:11 AM ET | Primary completion date | Jul 28, 2030 (sponsor estimate) | Locked | Locked | |
| Nov 12, 2026, 8:11 AM ET | Status | Active, not recruiting | Locked | Locked | |
| Nov 12, 2026, 8:11 AM ET | Status | Enrolling by invitation | Locked | Locked | |
| Nov 12, 2026, 8:11 AM ET | Completion date | Oct 29, 2029 (sponsor estimate) | Locked | Locked | |
| Nov 12, 2026, 8:11 AM ET | Primary completion date | Oct 27, 2027 (sponsor estimate) | Locked | Locked | |
| Nov 12, 2026, 8:11 AM ET | Status | Active, not recruiting | Locked | Locked |
- Detected Nov 19, 2026, 8:47 AM ETCompletion dateNCT07422285Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous DoseAMGN
- Now
- Jul 31, 2026 (actual)
- Before
- Locked
- Detected Nov 16, 2026, 8:47 AM ETCompletion dateNCT06680622Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at...AMGN
- Now
- Oct 26, 2026 (actual)
- Before
- Locked
- Detected Nov 16, 2026, 8:47 AM ETPrimary completion dateNCT06680622Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at...AMGN
- Now
- Jul 9, 2026 (actual)
- Before
- Locked
- Detected Nov 16, 2026, 8:47 AM ETStatusNCT06680622Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at...AMGN
- Now
- Completed
- Before
- Locked
- Detected Nov 13, 2026, 9:47 AM ETStatusNCT07222553Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RDAMGN
- Now
- Recruiting
- Before
- Locked
- Detected Nov 12, 2026, 8:11 AM ETCompletion dateNCT04221542Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate CancerAMGNONC
- Now
- Jul 29, 2032 (sponsor estimate)
- Before
- Locked
- Detected Nov 12, 2026, 8:11 AM ETPrimary completion dateNCT04221542Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate CancerAMGNONC
- Now
- Jul 28, 2030 (sponsor estimate)
- Before
- Locked
- Detected Nov 12, 2026, 8:11 AM ETStatusNCT07192237Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive...AMGN
- Now
- Active, not recruiting
- Before
- Locked
- Detected Nov 12, 2026, 8:11 AM ETStatusNCT07355894Health Enhanced Artery Risk Tracking With Widespread Implementation and Screening Effort in ASCVD (HEARTWISE-ASCVD)AMGN
- Now
- Enrolling by invitation
- Before
- Locked
- Detected Nov 12, 2026, 8:11 AM ETCompletion dateNCT07140900Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in...AMGN
- Now
- Oct 29, 2029 (sponsor estimate)
- Before
- Locked
- Detected Nov 12, 2026, 8:11 AM ETPrimary completion dateNCT07140900Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in...AMGN
- Now
- Oct 27, 2027 (sponsor estimate)
- Before
- Locked
- Detected Nov 12, 2026, 8:11 AM ETStatusNCT07140900Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in...AMGN
- Now
- Active, not recruiting
- Before
- Locked
The previous value and the sponsor's record update date are locked on 12 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerTracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.
What is on this list
Changes Signal8 recorded between two refreshes of a trial's ClinicalTrials.gov record: status, primary completion and completion dates, and results first posted. A change is shown when it was detected, which can be days after the sponsor updated the record. Nothing here describes what a trial showed.
New registrations, enrollment, eligibility and outcome-measure edits are not recorded. A status change is the registry's own word for where the trial stands, and "results posted" means results were posted to the registry, never what they show.
Free readers see the first 25 changes of any filter with the new value. The previous value, the sponsor's record update date and later pages are part of the plan. See the methodology.